AGP Executive Report
Last update: 4 hours agoChikungunya Vaccine: UK regulators have withdrawn authorization for Valneva’s IXCHIQ after reviewing existing safety data. The company says no newly identified safety issue prompted the decision and will not appeal. Approvals in the EU, Canada, Brazil and other markets remain unchanged, but the UK move adds uncertainty around a vaccine intended for travelers to chikungunya-affected regions.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.